CARDIFF ONCOLOGY, INC. Income Tax Examination, Penalties and Interest Expense
CARDIFF ONCOLOGY, INC. (CRDF) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-02-24
- CARDIFF ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- CARDIFF ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- CARDIFF ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- CARDIFF ONCOLOGY, INC. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 |
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-06 |
| 2017-12-31 | $0.00 10-K · filed 2018-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-10 |
| 2014-12-31 | $0.00 10-K · filed 2015-03-12 |
| 2013-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |